« Previous Next » American Journal of Cardiology
Volume 100, Issue 2 , Pages 222-226 , 15 July 2007

Effects of Valsartan Alone Versus Valsartan/Simvastatin Combination on Ambulatory Blood Pressure, C-Reactive Protein, Lipoproteins, and Monocyte Chemoattractant Protein–1 in Patients With Hyperlipidemia and Hypertension

Sanjay Rajagopalan, MD
- Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio
- Corresponding author: Tel: 641-247-2532; fax: 614-293-2561.
Faiez Zannad, MD
- Hypertension and Preventive Cardiology Division, Department of Cardiovascular Disease, University of Nancy, Nancy, France
- Dr. Zannad has received research grants/support from Pfizer, New York, New York; Servier, Neuilly-sur-Seine, France; and Bayer, Leverkusen, Germany; and honoraria from Guidant, Indianapolis, Indiana; and Servier, as well as served on the speakers’ bureaus for Pfizer, Servier, Novartis, Pharma, East Hanover, New Jersey; and Sankyo, Tokyo, Japan; and in a consultancy/advisory board capacity for Guidant.
Anca Radauceanu, PhD
- Hypertension and Preventive Cardiology Division, Department of Cardiovascular Disease, University of Nancy, Nancy, France
Robert Glazer, MD
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
Yan Jia, PhD
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
Margaret Forney Prescott, PhD
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
Mbabazi Kariisa, MPH
- Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio
Bertram Pitt, MD
- Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan.
- Dr. Pitt has received honoraria and served on the speakers’ bureau for Novartis, and acted in a consultancy/advisory board capacity for Novartis and Merck.

Received 8 November 2006 ,Revised 13 February 2007 ,Accepted 13 February 2007.

Study design and flow of patients through the trial. HCTZ = hydrochlorothiazide.

Study design and flow of patients through the trial. HCTZ = hydrochlorothiazide.
- Full-Size Image
- Download to PowerPoint
Between-treatment comparisons for least-square mean changes from baseline in (A) 24-hour mean ambulatory systolic BP and (B) 24-hour mean ambulatory diastolic BP at the end point (week 12; intent-to-t

Between-treatment comparisons for least-square mean changes from baseline in (A) 24-hour mean ambulatory systolic BP and (B) 24-hour mean ambulatory diastolic BP at the end point (week 12; intent-to-treat population). p = NS for between-treatment comparisons of least-square mean changes from baseline; p <0.0001 for within-treatment changes from baseline. n = number of patients with ambulatory BP values obtained over 24 hours at baseline and end point.
- Full-Size Image
- Download to PowerPoint
Between-treatment median changes from baseline in (A) hs-CRP and (B) monocyte chemoattractant protein–1 at end point (week 12; intent-to-treat population). ap = 0.0045 versus V; bp = 0.0023 versus V/S

Between-treatment median changes from baseline in (A) hs-CRP and (B) monocyte chemoattractant protein–1 at end point (week 12; intent-to-treat population). ^ap = 0.0045 versus V; ^bp = 0.0023 versus V/S20. n = number of patients with hs-CRP and monocyte chemoattractant protein–1 values obtained at baseline and end point.
- Full-Size Image
- Download to PowerPoint